-
The Swedish Medical Products Agency has authorised the emergency use of Eli Lilly's bamlanivimab in COVID-19 patients with underlying conditions that make them more vulnerable to the virus, as reported Xinhua on Thursday.
-
The drug is currently under review by the European Medicines Agency.
-
"It is in the approval process and as the results look promising, we believe that we can take advantage of this drug in a controlled way," said Charlotta Bergquist, group manager of efficacy and safety at the Swedish Medical Products Agency.
-
"Treatment should be started early in the course of the disease for those who risk becoming seriously ill," she added.
To read more NewsPoints articles, click here.
